Cebranopadol is a novel small molecule analgesic, which was discovered by Grünenthal. Cebranopadol represents a novel, first-in-class potent analgesic that has a dual mechanism of action as a potent agonist of both the nociceptin/orphanin FQ peptide receptor (NOP) and opioid peptide receptor. This difference in mechanism of action has several advantages. In animal models, cebranopadol demonstrated greater potency for neuropathic pain versus acute pain compared to selective MOP receptor agonist. Additionally, in animal models, NOP receptor agonists demonstrate comparably lower opioid-related side effects, such as respiratory depression.
LIST OF FIGURES
9 Figure 1: Cebranopadol for neuropathic pain – SWOT analysis
10 Figure 2: Datamonitor Healthcare’s drug assessment summary of cebranopadol for neuropathic pain
11 Figure 3: Datamonitor Healthcare’s drug assessment summary of cebranopadol for neuropathic pain
13 Figure 4: Cebranopadol sales for neuropathic pain across the five major EU markets, by country, 2017–26
LIST OF TABLES
6 Table 1: Cebranopadol drug profile
7 Table 2: Cebranopadol Phase II data in neuropathic pain
14 Table 3: Cebranopadol sales for neuropathic pain across the five major EU markets, by country ($m), 2017–26
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.